SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-24-006534
Filing Date
2024-05-02
Accepted
2024-05-02 16:01:24
Documents
15
Period of Report
2024-05-02
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K anvs-20240502x8k.htm   iXBRL 8-K 37251
2 EX-5.1 anvs-20240502xex5d1.htm EX-5.1 10462
3 GRAPHIC anvs-20240502xex5d1001.jpg GRAPHIC 7136
  Complete submission text file 0001558370-24-006534.txt   185109

Data Files

Seq Description Document Type Size
4 EX-101.SCH anvs-20240502.xsd EX-101.SCH 3400
5 EX-101.LAB anvs-20240502_lab.xml EX-101.LAB 16576
6 EX-101.PRE anvs-20240502_pre.xml EX-101.PRE 10713
18 EXTRACTED XBRL INSTANCE DOCUMENT anvs-20240502x8k_htm.xml XML 4980
Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

IRS No.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 24907988
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)